Acute Spinal Cord Injury Clinical Trial
— AFES and RMTOfficial title:
The Use of Functional Electrical Stimulation in Conjunction With Respiratory Muscle Training to Improve Unaided Cough in Individuals With Acute Spinal Cord Injury
NCT number | NCT05745298 |
Other study ID # | 20221081 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | July 21, 2023 |
Est. completion date | July 21, 2025 |
The overall objective of this study is to improve unaided cough with abdominal and latissimus dorsi functional electrical stimulation in conjunction with respiratory muscle training in individuals with acute spinal cord injuries.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | July 21, 2025 |
Est. primary completion date | July 21, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Traumatic and atraumatic C2- T12 Spinal cord injury (AIS A, B, and C motor incomplete and complete injuries) currently admitted to inpatient rehabilitation with an injury date < 12 months prior to enrollment 2. Positive response to electrical stimulation through a palpable contraction 3. Fluent in written and spoken English Exclusion Criteria: 1. Individuals who do not meet inclusion criteria 2. Prisoners 3. Concurrent traumatic brain injury determined by Rancho level of cognitive functioning < VI 4. Individuals with open tracheostomy 5. Persons with pacemakers 6. Pregnant women 7. Persons with epilepsy 8. Open wounds or metal implants at site of electrode placement 9. Unresponsive to functional electrical stimulation 10. Current diagnosis or history of thoraco-abdomino-pelvic cancer |
Country | Name | City | State |
---|---|---|---|
United States | University of Miami | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Miami |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage change in peak cough flow (PCF) | Assessing the percentage change in peak cough flow as assessed by peak expiratory flow meter with a pillow face mask. | one week pre-intervention and up to 4 weeks post-intervention | |
Primary | Percentage change in peak expiratory flow | Assessing the percentage change in peak expiratory flow as assessed by peak expiratory flow meter with a pillow face mask. | one week pre-intervention and up to 4 weeks post-intervention | |
Secondary | Percentage change in forced expiratory volume in 1 second (FEV1) | Assessing the percentage change in forced expiratory volume in 1 second (FEV1) as measured by the spirobank II. Measured in Liters/minute. | one week pre-intervention and up to 4 weeks post-intervention | |
Secondary | Percentage change in forced vital capacity (FVC) | Assessing the percentage change in forced vital capacity (FVC) as measured by the spirobank II. Measured in Liters/minute. | one week pre-intervention and up to 4 weeks post-intervention | |
Secondary | Percentage change in maximum inspiratory pressure (MIP) | Assessing the percentage change in maximum inspiratory pressure (MIP) as measured by the MicroSpiro. Measured in Liters/minute. | one week pre-intervention and up to 4 weeks post-intervention | |
Secondary | Percentage change in maximum expiratory pressure (MEP) | Assessing the percentage change in maximum expiratory pressure (MEP) as measured by the MicroSpiro. Measured in Liters/minute. | one week pre-intervention and up to 4 weeks post-intervention | |
Secondary | Change in cough effectiveness as measured by Likert Scale | The 5-point Likert scale will be used to obtain a self-rated perception of cough effectiveness. The participant will be asked to rate how strong and how well secretions were cleared after coughing. The rating scale will range from 1=very poor; 2=poor; 3=fair, 4=good; 5= very good. A score of 4 or 5 is classified as effectively clearing secretions after coughing. | one week pre-intervention and up to 4 weeks post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04811235 -
Optical Monitoring With Near-Infrared Spectroscopy for Spinal Cord Injury Trial
|
N/A | |
Completed |
NCT00406016 -
Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI
|
Phase 1 | |
Recruiting |
NCT05305118 -
TSCS for Acute SCI
|
N/A | |
Recruiting |
NCT05244408 -
"SCRIBBLE" Spinal Cord Injury Blood Biomarker Longitudinal Evaluation
|
||
Recruiting |
NCT05731986 -
Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI)
|
N/A | |
Recruiting |
NCT06452264 -
Early Intervention for Information Processing Speed Deficits in Acute SCI: A Pilot Study
|
N/A | |
Recruiting |
NCT05426681 -
Spinal Cord Injury Neuroprotection With Glyburide
|
Phase 1 | |
Recruiting |
NCT04056988 -
tSCI Contrast Enhanced Ultrasound Study
|
Phase 4 | |
Terminated |
NCT01750684 -
AC105 in Patients With Acute Traumatic Spinal Cord Injury
|
Phase 2 | |
Recruiting |
NCT04475224 -
Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
|
Phase 3 | |
Enrolling by invitation |
NCT06030531 -
Spasticity and Functional Recovery After SCI
|
||
Active, not recruiting |
NCT03935724 -
Stem Cells in Spinal Cord Injury
|
Phase 2/Phase 3 | |
Recruiting |
NCT04054414 -
PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
|
Phase 2 | |
Recruiting |
NCT06000592 -
Safety, Feasibility, and Efficacy of TSCS on Stabilizing Blood Pressure for Acute Inpatients With SCI
|
N/A | |
Completed |
NCT02325414 -
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
|
Phase 2 | |
Recruiting |
NCT02034669 -
Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Spinal Cord Injury Treatment
|
Phase 1/Phase 2 | |
Terminated |
NCT02232165 -
Mean Arterial Blood Pressure Treatment for Acute Spinal Cord Injury
|
N/A | |
Completed |
NCT02260713 -
Autologous Bone Marrow Cell Transplantation in Persons With Acute Spinal Cord Injury- An Indian Pilot Study.
|
Phase 1/Phase 2 | |
Terminated |
NCT02524379 -
Spinal Cord Injury Neuroprotection With Glyburide
|
Phase 1/Phase 2 | |
Completed |
NCT01502631 -
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)
|
Phase 2 |